Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Trastuzumab Rezetecan and Adebrelimab as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer

31. mai 2026 oppdatert av: Xu Yangyang, Harbin Medical University

Neoadjuvant Trastuzumab Rezetecan and Adebrelimab for HER2-positive Muscle-invasive Bladder Cancer: a Phase II, Prospective, Single-arm, Multicenter Trial

This study aims to evaluate the efficacy and safety of neoadjuvant trastuzumab rezetecan combined with adebrelimab for the treatment of HER2-positive muscle-invasive bladder cancer.

Studieoversikt

Status

Har ikke rekruttert ennå

Detaljert beskrivelse

Bladder cancer is an aggressive malignancy with a poor prognosis, ranking 13th globally in cancer incidence and first among urological tumors in China, with an increasing trend observed in urban cancer surveillance. Traditional treatments, including radical cystectomy and platinum-based chemotherapy, have limitations such as chemotherapy resistance and reduced postoperative quality of life. Recently, immune checkpoint inhibitors and antibody-drug conjugates (ADCs) have become research hotspots. This prospective, single-arm, multicenter clinical study aims to preliminarily evaluate the efficacy and safety of Trastuzumab Rezetecan combined with Adebrelimab as neoadjuvant therapy for HER2-expressing muscle-invasive bladder cancer (MIBC). A total of 58 eligible patients will be enrolled. The study includes screening, neoadjuvant treatment, and follow-up periods. During screening, untreated HER2-expressing MIBC patients eligible for radical surgery will be enrolled, with the period from informed consent to first dose not exceeding 28 days. The neoadjuvant treatment consists of Trastuzumab Rezetecan 3.2 mg/kg Q3W and Adebrelimab 1200 mg Q3W for three cycles. Patients will undergo imaging and surgical assessment 3-4 weeks after the last neoadjuvant treatment; those meeting surgical criteria will receive either transurethral resection or radical cystectomy. In the follow-up period, patients who proceed to surgery after neoadjuvant treatment will undergo postoperative safety monitoring and long-term survival follow-up.

Studietype

Intervensjonell

Registrering (Antatt)

58

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  1. Age ≥18 years.
  2. ECOG performance status of 0 or 1.
  3. Histopathologically diagnosed muscle-invasive bladder cancer (MIBC) (cT2-T4a, N0-1, M0).
  4. Tumor tissue with HER2 expression (IHC 2+ or 3+) and suitable for radical cystectomy (RC) and transurethral resection of bladder tumor (TURBT).
  5. No prior systemic chemotherapy.
  6. At least one measurable lesion per RECIST v1.1 (spiral CT long diameter ≥10 mm or short diameter of enlarged lymph node ≥15 mm) before diagnostic surgery.
  7. Adequate organ function (no transfusion or hematopoietic growth factor within 2 weeks before blood count screening):

    ANC ≥1.5×10⁹/L

    PLT ≥100×10⁹/L

    Hb ≥90 g/L

    TBIL ≤1.5×ULN (except subjects with Gilbert's syndrome)

    ALT and AST ≤2.5×ULN

    Cr ≤1.5×ULN

    LVEF ≥50%

    QTcF ≤450 ms

  8. Females of childbearing potential must agree to abstain from heterosexual intercourse or use reliable, effective contraception from signing informed consent until at least 120 days after the last dose of study drug; serum HCG must be negative within 7 days before starting study treatment; and must be non-lactating.
  9. A female is considered of childbearing potential if she has reached menarche, is not postmenopausal (≥12 consecutive months of amenorrhea without other cause), and has not undergone sterilization surgery (e.g., hysterectomy, bilateral tubal ligation, or bilateral oophorectomy).
  10. Male patients with partners of childbearing potential must agree to abstain from heterosexual intercourse or use reliable, effective contraception from signing informed consent until at least 120 days after the last dose of study drug. During the same period, male subjects must also agree not to donate sperm. Male subjects with pregnant partners must use a condom and no additional contraception is required.
  11. Subjects voluntarily join the study, sign written informed consent, and are expected to have good compliance with the study protocol.

Exclusion Criteria:

  1. Patients with any active autoimmune disease or history of autoimmune disease (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, etc.); patients with vitiligo; patients with childhood asthma that has completely resolved and requires no intervention in adulthood may be included; patients with asthma requiring bronchodilators for medical intervention are excluded.
  2. Patients currently using immunosuppressants or systemic corticosteroids for immunosuppressive purposes (dose >10 mg/day prednisone or equivalent) and continuing use within 2 weeks before the first dose.
  3. History of severe allergic reactions to other monoclonal antibodies.
  4. Subjects with untreated central nervous system (CNS) metastases; subjects who have received prior systemic, radical treatment for brain or leptomeningeal metastases (radiotherapy or surgery) may be included if imaging confirms stability for at least 1 month, systemic corticosteroid therapy (dose >10 mg/day prednisone or equivalent) has been discontinued for more than 2 weeks, and they are asymptomatic.
  5. Hypertension that cannot be well controlled with antihypertensive medication (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg).
  6. Poorly controlled cardiac clinical symptoms or diseases, including: 1) NYHA class ≥2 heart failure; 2) unstable angina; 3) myocardial infarction within 1 year; 4) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention; 5) QTc >450 ms (male) or QTc >470 ms (female); 6) Left ventricular ejection fraction (LVEF) ≤50% (i.e., EF >50% is required for inclusion).
  7. Abnormal coagulation function (INR >2.0, PT >16 s), bleeding tendency, or currently receiving thrombolytic or anticoagulant therapy; prophylactic use of low-dose aspirin or low molecular weight heparin is permitted.
  8. Bleeding events of grade ≥2 per CTCAE v6.0 within 4 weeks before the first dose.
  9. Imaging shows tumor invasion into major blood vessels, or the investigator judges that the tumor has a very high possibility of invading major blood vessels during treatment, leading to fatal massive hemorrhage.
  10. Arterial/venous thrombotic events within 6 months before the first dose, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism.
  11. Patients who received prior chemotherapy (including platinum-based chemotherapy) or surgery less than 4 weeks before study drug administration; palliative radiotherapy less than 2 weeks before study drug administration; molecular targeted therapy (including other oral targeted drugs in clinical trials) within less than 5 half-lives before the first study drug dose, or prior treatment-related adverse events (excluding alopecia) not recovered to ≤CTCAE grade 1.
  12. Patients with radiation enteritis caused by pelvic radiotherapy within 12 months before study drug administration.
  13. Active infection, unexplained fever ≥38.5°C within 7 days before dosing, or baseline white blood cell count >15×10⁹/L.
  14. Known history or evidence of interstitial lung disease or non-infectious pneumonitis that has required corticosteroid therapy; or patients who may interfere with the detection or management of suspected drug-related pulmonary toxicity.
  15. History of immunodeficiency, including positive HIV serology, or other acquired or congenital immunodeficiency diseases, or known active tuberculosis.
  16. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (HBV reference: HBsAg positive and HBV DNA ≥500 IU/ml; HCV reference: HCV antibody positive and HCV viral load > upper limit of normal).
  17. Patients with another malignancy within the past 5 years or concurrently (excluding cured basal cell carcinoma of the skin and carcinoma in situ of the cervix; for patients with recurrent ovarian cancer with prior history of breast cancer, those with no recurrence for >3 years after radical breast cancer surgery are excluded).
  18. Prior treatment with anti-PD-1, anti-PD-L1, anti-CTLA-4 antibodies (or any other antibodies targeting T-cell co-stimulatory or checkpoint pathways).
  19. Receipt of live vaccine within 4 weeks before the first dose or possible receipt during the study period.
  20. Pregnant or breastfeeding female patients.
  21. Patients judged by the investigator to have other conditions that may affect the conduct of the clinical study, inability to comply with the protocol, or lack of cooperation, or patients at risk of study participation.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Experimental Group
Trastuzumab Rezetecan Combined with Adebelizumab
Trastuzumab Rezetecan 3.2 mg/kg, Q3W, in combination with Adebrelimab 1200 mg, Q3W, for a total of 3 cycles. Subjects will undergo preoperative imaging and surgical eligibility assessment at 3-4 weeks after the last dose of neoadjuvant therapy. Those who meet the surgical criteria will receive either transurethral resection or radical resection.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Pathological Complete Response
Tidsramme: Assessed post-surgery (radical cystectomy or TURBT) on resected tumor specimens after neoadjuvant therapy. Measured postoperatively, up to approximately 4 months after treatment start.
Assessed by pathological evaluation of resected bladder cancer specimens after neoadjuvant therapy, defined as the proportion of patients with no residual tumor (pT0N0).
Assessed post-surgery (radical cystectomy or TURBT) on resected tumor specimens after neoadjuvant therapy. Measured postoperatively, up to approximately 4 months after treatment start.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Clinical Complete Response Rate
Tidsramme: Assessed by preoperative imaging and surgical evaluation at 3-4 weeks after the last neoadjuvant dose. Up to approximately 4 months after treatment start.
Assessed by preoperative imaging (CT/MRI) and urine cytology after neoadjuvant therapy, defined as the proportion of patients with no residual tumor on imaging, negative urine cytology, and no evidence of nodal or distant metastasis.
Assessed by preoperative imaging and surgical evaluation at 3-4 weeks after the last neoadjuvant dose. Up to approximately 4 months after treatment start.
Pathological Downstaging Rate
Tidsramme: Assessed simultaneously with pCR on postoperative pathological staging. Up to approximately 4 months after treatment start.
Assessed by postoperative pathological staging, defined as the proportion of patients with ypT < T2 and ypN = N0 after neoadjuvant therapy.
Assessed simultaneously with pCR on postoperative pathological staging. Up to approximately 4 months after treatment start.
Event-Free Survival
Tidsramme: Time from treatment start to first occurrence of disease progression, recurrence, second primary tumor, or death. Continuously assessed during follow-up, maximum follow-up of 36 months.
Time from first dose to first occurrence of disease progression, recurrence, second primary tumor, or death from any cause.
Time from treatment start to first occurrence of disease progression, recurrence, second primary tumor, or death. Continuously assessed during follow-up, maximum follow-up of 36 months.
Overall Survival
Tidsramme: Time from treatment start to death from any cause. Continuously assessed, maximum follow-up of 36 months.
Time from first dose to death from any cause.
Time from treatment start to death from any cause. Continuously assessed, maximum follow-up of 36 months.
QoL Score
Tidsramme: Assessed by EORTC QLQ-C30 V3.0 at screening, Day 1 of each 21-day cycle (3 cycles), pre-surgery, post-surgery q30d ×3, then q3m (Year 1) and q6m (Years 2-3), up to 36 months.
Assessed using the EORTC QLQ-C30 V3.0 patient-reported questionnaire at screening, each treatment cycle, end of treatment, and follow-up visits.
Assessed by EORTC QLQ-C30 V3.0 at screening, Day 1 of each 21-day cycle (3 cycles), pre-surgery, post-surgery q30d ×3, then q3m (Year 1) and q6m (Years 2-3), up to 36 months.
Adverse event incidence
Tidsramme: AEs/SAEs/lab abnormalities collected from informed consent to 30 days post-last dose (safety follow-up). Surgical endpoints assessed postoperatively. Only treatment-related SAEs collected during survival follow-up, up to 36 months.
AEs and laboratory abnormalities graded by NCI CTCAE v6.0; SAEs recorded separately; surgical endpoints (feasibility, delay/cancellation rate, procedure change, operation duration) collected from postoperative clinical records and surgical logs.
AEs/SAEs/lab abnormalities collected from informed consent to 30 days post-last dose (safety follow-up). Surgical endpoints assessed postoperatively. Only treatment-related SAEs collected during survival follow-up, up to 36 months.
Exploratory Biomarkers
Tidsramme: Blood and tumor samples at baseline, C2D1, C3D1 (21-day cycles), at progression, and at EOT (after 3 cycles/pre-surgery). Max collection ~4 months; no routine survival follow-up sampling.
Blood and tumor tissue samples collected at baseline, during treatment, and at end of treatment to assess PD-L1, HER2, and other markers for correlation with efficacy (e.g., pCR, EFS).
Blood and tumor samples at baseline, C2D1, C3D1 (21-day cycles), at progression, and at EOT (after 3 cycles/pre-surgery). Max collection ~4 months; no routine survival follow-up sampling.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. juni 2026

Primær fullføring (Antatt)

1. juni 2028

Studiet fullført (Antatt)

1. juni 2029

Datoer for studieregistrering

Først innsendt

21. mai 2026

Først innsendt som oppfylte QC-kriteriene

31. mai 2026

Først lagt ut (Faktiske)

3. juni 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

3. juni 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

31. mai 2026

Sist bekreftet

1. mai 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • SHR-A1811-1316-BC

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere